Minerva Neurosciences (NERV) Current Deferred Revenue (2014 - 2016)
Minerva Neurosciences' (NERV) quarterly Current Deferred Revenue came in at $3.5 million in Q3 2016, up 42801.4% on a QoQ basis from $8237.0 in Q1 2015.
Powered by 
Analysis
Minerva Neurosciences (NERV) Current Deferred Revenue (2014 - 2016) Analysis & Trends
Minerva Neurosciences (NERV) has 3 years of Current Deferred Revenue data on file, last reported at $3.5 million in Q3 2016.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $3.5 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $3.5 million (changed N/A YoY) and the FY2014 annual result came in at $7226.0, changed N/A from the prior year.
- Current Deferred Revenue improved to $3.5 million in Q3 2016, from $8237.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.5 million in Q3 2016 to a low of $7226.0 in Q4 2014.
- A 3-year average of $1.2 million and a median of $8237.0 in 2015 frame the typical range for Current Deferred Revenue.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2016 | 3.53 Mn |
| Mar 31, 2015 | 8,237.00 |
| Dec 31, 2014 | 7,226.00 |